- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01600300
Efficacy of Electrical Micro-current Retinal Stimulation for Treatment of Dry Age-related Macular Degeneration
May 15, 2012 updated by: Acuity Medical International, Inc.
A Double-Blind, Placebo-Controlled Feasibility Study to Evaluate the Efficacy of TESMAC™ (Transcutaneous Electrical Stimulation of the Macula)
Hypothesis: external electrical stimulation of the retina with low level electrical currents improves visual acuity in subjects with age-related dry macular degeneration.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Phase 2
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of Macular Degeneration, i.e., at least three, hard or soft drusen must be present there must be RPE changes (migration, clumping or atrophy) within the central 6mm of the retina.
- As a prerequisite for entry into the study, all patients will have their diagnosis of dry AMD confirmed by an ophthalmologist via a retinal exam and Fluorescein Angiography will also determine whether or not the subject is a candidate for laser surgery. Only subjects who have AMD will be admitted to the study.
- Both sexes are eligible.
- The best-corrected visual acuity can be no better than 20/40 and no worse than 20/100 in the treated eyes.
- Age greater than 50.
- Subjects must be highly motivated, alert, oriented, mentally competent and able to understand and comply with the requirements of the study, abide by the restrictions, return for all required visits, and provide voluntary informed consent.
- Both eyes of the subject must show no evidence of wet AMD. If one eye is wet and the fellow eye is dry, the subject will be excluded.
Exclusion Criteria:
- Subjects with seizure disorders.
- Subjects with additional eye-related diseases that have associated ongoing retinal bleeding.
- Subjects with any implanted electrical device.
- Subjects who have smoked, on average, more than half a pack of cigarettes per day during the last 5 years.
- Subjects with known allergy to contrast dye.
- Subjects who are in poor general health, have unstable diseases, are terminally ill, have a life expectancy of less than 12 months, are non-ambulatory or bedridden, live in a geographical location which would likely prevent regular attendance at study visits or are considered not suitable for participation by the investigator.
- Subjects exposed to an investigational device or drug within the past 30 days or involved concurrently in other treatment clinical trials. Note: Subjects participating in studies investigating the natural progression of AMD may not participate in this trial.
- Subjects unwilling to adhere to visit or examination schedules as described in the study protocol.
- Subjects with a known history of alcoholism, drug abuse, psychosis, clinical evidence of depression, poor motivation, emotional or intellectual problems, or any other conditions which would likely limit validity of consent or appropriate responses to participate in the study or who are deemed unsuitable psychologically or physiologically for study participation by the investigator.
- Any subject experiencing an acute stressor that, in the opinion of the investigator, might affect the course or treatment of AMD.
- Anyone with diagnosis of malignant or poorly controlled glaucoma in the eye(s) that would be treated.
- Anyone with diabetic retinopathy.
- Anyone with a progressive corneal dystrophy in the eye(s) that would be treated.
- Anyone with any noted chorio retinal disease (other than AMD) in the eye(s) that would be treated.
- Anyone with a progressive nuclear cataract in the eye(s) that would be treated. Stable cortical cataract patients may be included. Any patient with an immature cataract, one in which scattered opacities are separated by clear zones, may be included in the study. All patients with mature, hypermature or morgagnian cataracts in the eye(s) that would be treated will be excluded. Patients with a grade 3 or grade 4 cataract in the eye(s) that would be treated will be excluded. Grade 1 and Grade 2 cataract patients may be included in this study.
- Subjects participating in an AMD natural history study.
- Subjects with one eye diagnosed with wet AMD.
- Subjects with any previous retinal bleeding, injury, or retinal surgery.
- Subjects that have previously been diagnosed with amblyopia.
- Subjects currently taking blood-thinning medication.
- Subjects cannot have previously been involved in a TESMAC™ study.
- Subjects that take two or more of the following antioxidants daily at the following doses: 500 milligrams of vitamin C; 400 international units of vitamin E; 15 milligrams of beta-carotene; 80 milligrams of zinc as zinc oxide; and two milligrams of copper as cupric oxide and have done this for more than 2 years. These subjects may be included, but their study results will be analyzed separately.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Sham
Treatment with inactivate Tesmac device
|
Treatment with inactivated Tesmac device on the same schedule as the group treated with the active Tesmac device.
|
Active Comparator: Tesmac
Treatment with active Tesmac device
|
Subjects were treated twice daily for five consecutive days, followed by two days untreated, and then treated twice daily for five more consecutive days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in visual acuity
Time Frame: Day 5, Day 12
|
Change in visual acuity as measured with ETDRS eye chart
|
Day 5, Day 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Richard Beauchemin, MD, WNC Eye Care Associates PA
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2002
Primary Completion (Actual)
April 1, 2004
Study Completion (Actual)
April 1, 2004
Study Registration Dates
First Submitted
May 14, 2012
First Submitted That Met QC Criteria
May 15, 2012
First Posted (Estimate)
May 17, 2012
Study Record Updates
Last Update Posted (Estimate)
May 17, 2012
Last Update Submitted That Met QC Criteria
May 15, 2012
Last Verified
May 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TESMAC-2002.2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Macular Degeneration
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular Degeneration
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Hoffmann-La RocheRecruitingNeovascular Age Related Macular Degeneration | nAMDChina
-
Shanghai Refreshgene Technology Co., Ltd.RecruitingNeovascular Age-related Macular DegenerationChina
-
PharmAbcineC&R Research, Inc.RecruitingNeovascular Age-related Macular DegenerationKorea, Republic of
-
Olix Pharmaceuticals, Inc.Trial Runners, LLCRecruitingNeovascular Age-related Macular DegenerationUnited States
-
Seoul National University Bundang HospitalRecruitingNeovascular Age-related Macular DegenerationKorea, Republic of
Clinical Trials on Sham Tesmac device
-
Medical University of South CarolinaCompletedUse of Novel Sinusonic Device for Prevention of Community Acquired Upper Respiratory Infection (URI)Upper Respiratory InfectionUnited States
-
Neurolief Ltd.Terminated
-
Neurolief Ltd.Completed
-
Neuroelectrics CorporationRecruitingEpilepsy | Seizures | Refractory Epilepsy | Epilepsy, Tonic-Clonic | Epilepsy in Children | Seizures, Focal | Focal SeizureSpain, United States, France, Belgium
-
Thimble Bioelectronics, Inc.University of California, San FranciscoWithdrawn
-
OrthoAccel Technologies Inc.Completed
-
ZetrOZ, Inc.State University of New York - Upstate Medical UniversityTerminated
-
J3 Bioscience, Inc.Advanced Clinical Research, Inc.; Phil Triolo and Associates LCCompletedPostmenopausal Symptoms | Menopause Related ConditionsUnited States
-
Northwell HealthUniversity of OklahomaRecruitingPremature Ventricular ContractionUnited States
-
Pressure Profile Systems, Inc.The Cleveland Clinic; Kaiser Permanente; Mission Pain and SpineCompleted